Compulsory licensing : India's maiden experience

Files

IDL-54301.pdf (580.33 KB)

Date

2013-12

Authors

Journal Title

Journal ISSN

Volume Title

Publisher

ARTNeT, United Nations ESCAP

Abstract

In the battle between patents and patients, this paper details the first attempt by the Indian patent system to strike a balance between the innovator’s legal and economic rights and the public interest policies of the Government, whereby it granted its first compulsory license to a domestic company for manufacturing and selling a generic version of an anti-cancer drug. Although this action was contested at the Intellectual Property Appellate Board, the final decision was in favor of the issuing of the compulsory license. Possible implications for various stakeholders are reasoned out through a cost-benefit analysis approach.

Description

Keywords

INTELLECTUAL PROPERTY, GENERIC DRUGS, PHARMACEUTICAL INDUSTRY, LICENSING, WTO, PATENT LAW, POLICY MONITORING, DISEASE CONTROL, DRUG POLICY, PRICING

Citation

URI

http://hdl.handle.net/10625/54301
 http://www.unescap.org/sites/default/files/AWP%20No.%20137.pdf

DOI

Collections

IDRC Research Results / Résultats de recherches du CRDI
2010-2019 / Années 2010-2019
Research Results (SIG) / Résultats de recherches (CPT)